Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Assets (2021 - 2025)

Vivos Therapeutics (VVOS) has disclosed Return on Assets for 5 consecutive years, with 0.66% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets rose 15.0% to 0.66% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.66%, a 15.0% increase, with the full-year FY2024 number at 0.86%, up 26.0% from a year prior.
  • Return on Assets was 0.66% for Q3 2025 at Vivos Therapeutics, up from 0.77% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.71% in Q3 2023 to a low of 1.39% in Q1 2024.
  • A 5-year average of 0.57% and a median of 0.7% in 2022 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: soared 189bps in 2023, then plummeted -163bps in 2024.
  • Vivos Therapeutics' Return on Assets stood at 0.54% in 2021, then soared by 101bps to 0.01% in 2022, then tumbled by -20895bps to 1.29% in 2023, then surged by 44bps to 0.73% in 2024, then rose by 9bps to 0.66% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Return on Assets are 0.66% (Q3 2025), 0.77% (Q2 2025), and 0.85% (Q1 2025).